Jatinkumar Machhi, PhD

Jatinkumar Machhi, PhDJatinkumar Machhi, PhD
Instructor


 

Laboratory: Howard E. Gendelman, MD
Movement Disorders Laboratory

Durham Research Center 3024
985930 Nebraska Medical Center
Omaha, NE 68198-5930
Phone: 402-559-2779

 

Keywords:

Alzheimer’s disease, Parkinson’s disease, neurodegenerative diseases, animal models, immunology, immunomodulation


Research Interests
Ongoing Projects
Representative Publications


Research Interests:  

My research areas include pharmacology, neuroimmunology and neurodegenerative diseases including Alzheimer’s and Parkinson’s disease. I am studying innate and adaptive immune arms, their contribution in the disease pathology, and how they can be harnessed for the therapeutics. I am focusing on the development of small drug molecules and immunotherapies for the potential treatment of neurodegenerative diseases. Additionally, I am developing next-generation Alzheimer’s disease mouse models to precisely understand the human disease mechanisms and better clinical translation of therapeutics. I am also working upon the infectious diseases including human immunodeficiency virus 1 (HIV-1) and coronavirus diseases 2019 (COVID-19) and their implications in neurodegenerative diseases.


Ongoing Projects:

  1. Adaptive immune alterations in Alzheimer’s disease

Immune system plays a viral role in homeostasis but gets disturbed over the progression of Alzheimer’s disease, an incurable form of dementia mainly characterized by the deposition of misfolded self-proteins amyloid beta (Aβ) and subsequent tau aggregates. Although the central nervous system (CNS) resident innate immune cells’ role in the disease pathogenesis is well studied over the past decades, peripheral adaptive immune responses are overlooked. To understand the precise role of disease operative adaptive immune cells, I am developing Aβ reactive CD4+ T cell subsets specifically of effector and regulatory phenotype and studying how each subset contributes to the pathology. Such understanding will allow us to harness body’s immune cells as a novel disease biomarkers and immunotherapies for the better management of patients who are currently relying only upon the symptomatic treatments.

 

  1. Development of next-generation Alzheimer’s disease mouse models

Since last two decades more than 400 drug candidates failed to demonstrate therapeutic efficacy in the clinical trials of Alzheimer’s disease despite encouraging preclinical results suggesting that existing animal models originally developed in 90’s lack important biological features of the human disease. To overcome these limitations, I am developing next-generation animal models (APP, PS1 and Tau knock-in) that exhibit all the human disease components without offering undesired artificial phenotypes. The key advantage of newer mice models includes establishment of complete human immune system both in the CNS and periphery under the vicinity of human pathological proteins. Successful development of these models will offer a better platform to the scientific community for clinical translation of therapeutics and understanding precise pathological mechanisms.    

Publications:

  1. Jatin Machhi, Farah Shahjin, Srijanee Das, Milankumar Patel, Mai Mohamed Abdelmoaty, Jacob D. Cohen, Preet Amol Singh, Ashish Baldi, Neha Bajwa, Raj Kumar, Lalit K. Vora, Tapan A. Patel, Maxim D. Oleynikov, Dhruvkumar Soni, Pravin Yeapuri, Insiya Mukadam, Rajashree Chakraborty, Caroline G. Saksena, Jonathan Herskovitz, Mahmudul Hasan, David Oupicky, Suvarthi Das, Ryan F. Donnelly, Kenneth S. Hettie, Linda Chang, Howard E. Gendelman, Bhavesh D. Kevadiya. Nanocarrier Vaccines for SARS-CoV-2. Advanced Drug Delivery Reviews
  2. Jatin Machhi, Farah Shahjin, Srijanee Das, Milankumar Patel, Mai Mohamed Abdelmoaty, Jacob D. Cohen, Preet Amol Singh, Ashish Baldi, Neha Bajwa, Raj Kumar, Lalit K. Vora, Tapan A. Patel, Maxim D. Oleynikov, Dhruvkumar Soni, Pravin Yeapuri, Insiya Mukadam, Rajashree Chakraborty, Caroline G. Saksena, Jonathan Herskovitz, Mahmudul Hasan, David Oupicky, Suvarthi Das, Ryan F. Donnelly, Kenneth S. Hettie, Linda Chang, Howard E. Gendelman, Bhavesh D. Kevadiya. A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention. Journal of Neuroimmune Pharmacology
  3. Bhavesh D Kevadiya, Jatin Machhi, Jonathan Herskovitz, Maxim D Oleynikov, Wilson R Blomberg, Neha Bajwa, Dhruvkumar Soni, Srijanee Das, Mahmudul Hasan, Milankumar Patel, Ahmed M Senan, Santhi Gorantla, JoEllyn McMillan, Benson Edagwa, Robert Eisenberg, Channabasavaiah B Gurumurthy, St Patrick M Reid, Chamindie Punyadeera, Linda Chang, Howard E Gendelman. Diagnostics for SARS-CoV-2 Infections. Nature Materials
  4. Bhavesh D Kevadiya, Jatin Machhi, Jonathan Herskovitz, Maxim D Oleynikov, Wilson R Blomberg, Neha Bajwa, Dhruvkumar Soni, Srijanee Das, Mahmudul Hasan, Milankumar Patel, Ahmed M Senan, Santhi Gorantla, JoEllyn McMillan, Benson Edagwa, Robert Eisenberg, Channabasavaiah B Gurumurthy, St Patrick M Reid, Chamindie Punyadeera, Linda Chang, Howard E Gendelman. Pharmacotherapeutics of SARS-CoV-2 Infections. Journal of Neuroimmune Pharmacology
  5. Jatin Machhi, Jonathan Herskovitz, Ahmed M Senan, Debashis Dutta, Barnali Nath, Maxim D Oleynikov, Wilson R Blomberg, Douglas D Meigs, Mahmudul Hasan, Milankumar Patel, Peter Kline, Raymond Chuen-Chung Chang, Linda Chang, Howard E Gendelman, Bhavesh D Kevadiya. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. Journal of Neuroimmune Pharmacology 2020; 21:1-28.
  6. Jatin Machhi, Bhavesh D Kevadiya, Ijaz Khan Muhammad, Jonathan Herskovitz, Katherine E Olson, R Lee Mosley, Howard E Gendelman. Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Molecular Neurodegeneration 2020; 15:32.
  7. Insiya Z Mukadam, Jatin Machhi, Jonathan Herskovitz, Mahmudul Hasan, Maxim D Oleynikov, Wilson R Blomberg, Denis Svechkarev, Aaron M Mohs, You Zhou, Prasanta Dash, JoEllyn McMillan, Santhi Gorantla, Jered Garrison, Howard E Gendelman, Bhavesh D Kevadiya. Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking. Biomaterials 2020; 231:119669.
  8. Aaron D. Schwab, Mackenzie J. Thurston, Jatin Machhi, Katherine E Olson, Krista L Namminga, Howard E Gendelman, R Lee Mosley. Immunotherapy for Parkinson's disease. Neurobiology of Disease 2020; 137:104760.
  9. Bhavesh D Kevadiya, Brendan Ottemann, Insiya Z Mukadam, Laura Castellanos, Kristen Sikora, James R Hilaire, Jatin Machhi, Jonathan Herskovitz, Dhruvkumar Soni, Mahmudul Hasan, Wenting Zhang, Sarella Anandakumar, Jered Garrison, JoEllyn McMillan, Benson Edagwa, R Lee Mosley, Richard W Vachet, Howard E Gendelman. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. Theranostics 2020; 10:630.
  10. R Lee Mosley, Yaman Lu, Katherine E Olson, Jatin Machhi, Wenhui Yan, Krista L Namminga, Jenell R Smith, Scott J Shandler, Howard E Gendelman. A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease. Frontiers in Cellular Neuroscience 2019; 13:421.

Additional publications in PubMed

Top of page.